Ge Long Hui A P P·2025-08-18 06:17Core Viewpoint - Rongchang Biologics has announced plans to submit a listing application for its self-developed dual-target fusion protein innovative drug, Tai Ta Xi Pu, to the National Medical Products Administration (NMPA) and will present detailed data at major international academic conferences [1] Group 1: Product Development - The company's RC148 has received FDA approval to conduct Phase II clinical trials in the United States for various advanced malignant solid tumors, marking its entry into global clinical research [1] - The approval of RC148 is expected to enhance its international clinical value and potential for overseas expansion [1] Group 2: Financial Forecast - The company maintains its net loss forecasts for 2025 and 2026 at 915 million yuan and 333 million yuan, respectively [1] - Positive Phase III clinical results for Tai Ta Xi Pu in dry syndrome are anticipated to increase its future value potential [1] Group 3: Investment Rating - The firm maintains a "outperforming the industry" rating for Rongchang Biologics and raises the target price by 24.8% to 95.34 HKD [1]